CSBio CSBio

X
[{"orgOrder":0,"company":"Cevec","sponsor":"Biogen","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Cevec Announces New License Agreement for Its Aav Manufacturing Technology Elevecta\u00ae IN Gene Therapy","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Cell and Gene therapy","productStatus":"New Molecular Entity","date":"January 2021","url1":"","url2":"","graph1":"Cell and Gene therapy","graph2":"Cevec"},{"orgOrder":0,"company":"Evotec","sponsor":"Bristol Myers Squibb","pharmaFlowCategory":"D","amount":"$285.0 million","upfrontCash":"Undisclosed","newsHeadline":"Evotec Expands Neuroscience Collaboration with Bristol Myers Squibb to Include New Targeted Protein Degradation Approach","therapeuticArea":"Neurology","highestDevelopmentStatus":"Discovery Platform","country":"GERMANY","productType":"Undisclosed","productStatus":"Undisclosed","date":"January 2022","url1":"","url2":"","graph1":"Undisclosed","graph2":"Evotec"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Loading...
Filters Filter
×
FILTER:
filter News Type
    filter Company
      filter Product Type
        filter Deal Size
          filter Upfront Payment

            Active Filter(s):

            Product Type

            Companies

            Details:

            Under the expansion, Bristol Myers Squibb increases its access to a novel targeted protein degradation approach. The focus will be on selected targets that are relevant to a range of neurodegenerative conditions.

            Lead Product(s): Undisclosed

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Undisclosed

            Partner/Sponsor/Collaborator: Bristol Myers Squibb

            Deal Size: $285.0 million Upfront Cash: Undisclosed

            Deal Type: Expanded Collaboration January 11, 2022

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity

            Details:

            Under the terms of the agreement, CEVEC grants Biogen a non-exclusive license for CEVEC’s ELEVECTA® Technology. The deal will afford Biogen the rights to use the technology across their portfolio of gene therapy products.

            Lead Product(s): AAV-based gene therapy

            Therapeutic Area: Neurology Product Name: Undisclosed

            Highest Development Status: Discovery Platform Product Type: Cell and Gene therapy

            Partner/Sponsor/Collaborator: Biogen

            Deal Size: Undisclosed Upfront Cash: Undisclosed

            Deal Type: Licensing Agreement January 08, 2021

            ASK
            US
            PHARMACOMPASS
            Upload
            your Pipeline Activity
            Post Enquiry
            POST ENQUIRY